Skip to main content
OpenTrials
Completed

NCT Number: NCT00881322

A Study on Intestinal Gas Symptoms to Evaluate the Effects of Gas Defense in Otherwise Healthy Adult

This is a randomized, double-blind, placebo-controlled trial to determine the safety and efficacy of Digestive Advantage™ Gas Defense formula, a probiotic dietary supplement. The study will last approximately four weeks, and subjects will be seen at a screening/randomization visit, and two follow-up visits.

Study procedures will include administering questionnaires for assessment of the study product's effect on intestinal gas symptoms and quality of life.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Latin American Research, Santo Domingo, Dominican Republic

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is 18-75 years of age.
  • Subject self-reports at least one of the following symptoms after eating a meal or snack:
  • Abdominal pain/cramps
  • Distended feeling/bloating
  • Flatulence/gas
  • Subject is in otherwise general good health as determined by physical exam and medical history.
  • Subject is willing and able to comply with the protocol.
  • Female subjects not defined as post-menopausal (excluding hysterectomized and post bilateral tubal ligations) must use a reliable method of birth control as defined within this protocol.
  • Subject is able to understand and sign the informed consent (English or Spanish) to participate in the study.

Exclusion criteria

  • Subject has any of the following medical conditions:
  • active heart disease
  • renal or hepatic impairment/disease
  • Type I or II diabetes
  • psychiatric disorders (hospitalized within the past one year)
  • bipolar disorder
  • Parkinson's disease
  • unstable thyroid disease
  • immune disorder (such as HIV/AIDS)
  • any medical condition deemed exclusionary by the Principal Investigator (PI)
  • Subject has a history of cancer (except localized skin cancer without metastases or in situ cervical cancer) within five years prior to screening.
  • Subject has had any stomach or intestinal surgery (i.e. gastric bypass).
  • Subject is currently taking antibiotics (or any drug that significantly interferes with bacterial flora) or has taken antibiotics within the 30 days prior to screening/enrollment.
  • Subject is currently taking or has used in the past 30 days probiotics or prebiotics.
  • Subject is on an unstable dose of medication (defined as fewer than 90 days at the same dose).
  • Subject is currently taking any medication deemed exclusionary by PI.
  • Subject has a history of or currently has any gastrointestinal disorders or inflammatory bowel conditions such as Crohn's disease, short bowel, or ulcerative colitis. Subjects may not have a diagnosis, be seeing a doctor, or taking prescription medication(s) for Irritable Bowel Syndrome (IBS).
  • Subject has constipation defined as less than three spontaneous bowel movements per week.
  • Subject is lactose intolerant (self-professed or diagnosed).
  • Subject uses any of the following classification of GI medications two or more times per week: anti-spasmodics, motility agents, pro-kinetic agents or laxatives.
  • Subject plans to use another over-the-counter gas-relief product daily during the study period. Over-the-counter gas relief products may be used as rescue medication (their use will be captured by the study staff). If a subject is using a fiber supplement prior to starting the study, he/she may continue as long as the frequency and quantity remain stable throughout the study period.
  • Subject has an allergy to wheat or fish or any of the other product ingredients (see section 2.5.4).
  • Subject has two or more food allergies.
  • Subject has a history of drug or alcohol abuse within the past 12 months.
  • Subject is deemed by the Investigator as an unsuitable candidate for receipt of an investigational dietary supplement, or unable to be followed up throughout the entire duration of the study.
  • Female subject of childbearing potential is unwilling to use an acceptable form of contraceptive device throughout the study period.
  • Subject is pregnant, lactating, or planning to become pregnant during the study period.
  • Subject is participating in another clinical trial or has received an investigational product within 30 days prior to screening/enrollment.
  • Subject is deemed by the Investigator as an unsuitable candidate for receipt of an investigational dietary supplement, or unable to be followed up throughout the entire duration of the study.
  • Subject is unable to comprehend the Informed Consent and research purpose.
  • Subject is unable or unwilling to comply with the protocol.

Treatment and study plan

BC-130 (Gas Defense)

Dietary Supplement

Product Dosing:

Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)

Gas Defense Serving Size: 1 tablet Active Ingredients: B. Coagulans, Enzyme Blend (Cellulase - Trichoderma longibrachiatum, Cellulase - Aspergillus niger, Hemicellulase, Alpha Galactosidase, Invertase) Inactive Ingredients: vegetable capsule, Magnesium Stearate, Silicon Dioxide, Maltodextrin Contains: Wheat, Fish.

Other names: Gas Defense

Placebo

Dietary Supplement

Product Dosing:

Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)

Placebo - matched in size and color to the active product Inactive Ingredients: microcrystalline cellulose, FD&C yellow #5 Lake, FD&C blue #1 Lake, FD&C red #46 Lake and vegetable capsule

Primary outcomes

  1. To determine the effect of daily supplementation with GD as compared to placebo on intestinal gas symptoms as measured by the subscores of the GI Symptom Rating Scale (GSRS) and the subscores of the Severity of Dyspepsia Assessment (SODA).

    Time frame: 4 weeks

  2. Primary Safety Objective To determine if daily supplementation with GD is safe within the confines of this study as denoted by changes from baseline in blood pressure, heart rate, adverse events, and subjective remarks.

    Time frame: 4 weeks

Sponsors and collaborators

Lead sponsor

Miami Research Associates

Network

Collaborators

  • Ganeden Biotech, Inc.

Registry information

Official study title

A Prospective, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Clinical Trial to Evaluate the Effects of Gas Defense On Intestinal Gas Symptoms in Otherwise Healthy Adults

Important dates

Study start
2008
Primary completion
2008
Study completion
2008
First posted
Apr 15, 2009
Registry last updated
Sep 30, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.